Free Trial

Dominari (DOMH) Competitors

Dominari logo
$4.80 -0.17 (-3.42%)
As of 02:31 PM Eastern

DOMH vs. XOMA, VNDA, VSTM, CDXS, SGMO, AGEN, IRWD, ACHV, FBIO, and CRIS

Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Sangamo Therapeutics (SGMO), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

Dominari vs. Its Competitors

XOMA Royalty (NASDAQ:XOMA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

XOMA Royalty has a net margin of -13.04% compared to Dominari's net margin of -167.73%. XOMA Royalty's return on equity of -12.43% beat Dominari's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA Royalty-13.04% -12.43% -4.85%
Dominari -167.73%-91.67%-77.80%

In the previous week, XOMA Royalty had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for XOMA Royalty and 0 mentions for Dominari. XOMA Royalty's average media sentiment score of 0.74 beat Dominari's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.

Company Overall Sentiment
XOMA Royalty Positive
Dominari Neutral

XOMA Royalty presently has a consensus target price of $69.50, suggesting a potential upside of 145.00%. Given XOMA Royalty's stronger consensus rating and higher possible upside, equities research analysts clearly believe XOMA Royalty is more favorable than Dominari.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dominari
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

XOMA Royalty has higher revenue and earnings than Dominari. XOMA Royalty is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA Royalty$28.49M11.92-$13.82M-$1.15-24.67
Dominari$18.15M3.87-$14.70M-$4.50-1.07

XOMA Royalty has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Comparatively, 33.0% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

XOMA Royalty beats Dominari on 14 of the 16 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DOMH vs. The Competition

MetricDominariMED IndustryMedical SectorNASDAQ Exchange
Market Cap$70.27M$2.43B$5.58B$9.03B
Dividend YieldN/A1.80%5.25%4.03%
P/E Ratio-1.079.3927.1820.17
Price / Sales3.87608.55415.50184.26
Price / CashN/A161.3437.0657.97
Price / Book0.844.688.085.60
Net Income-$14.70M$31.26M$3.16B$248.50M
7 Day Performance-8.92%6.64%3.64%5.07%
1 Month Performance-12.09%3.92%3.78%7.53%
1 Year Performance147.42%3.88%34.08%21.54%

Dominari Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DOMH
Dominari
0.3788 of 5 stars
$4.80
-3.4%
N/A+157.5%$70.27M$18.15M-1.074
XOMA
XOMA Royalty
4.3209 of 5 stars
$25.37
+0.7%
$69.50
+173.9%
+12.8%$302.12M$28.49M-21.9510
VNDA
Vanda Pharmaceuticals
4.3989 of 5 stars
$4.68
-0.8%
$16.50
+252.6%
-5.6%$276.68M$198.77M-6.26290News Coverage
VSTM
Verastem
2.5689 of 5 stars
$4.19
+0.8%
$13.38
+219.6%
+72.4%$229.75M$10K-1.3150
CDXS
Codexis
2.931 of 5 stars
$2.42
-1.0%
$11.00
+355.5%
-2.3%$200.91M$59.35M-2.45250
SGMO
Sangamo Therapeutics
2.733 of 5 stars
$0.52
-3.8%
$4.50
+763.7%
+50.3%$121.48M$57.80M-1.34480
AGEN
Agenus
4.3509 of 5 stars
$4.42
-3.3%
$14.00
+216.7%
-66.8%$121.20M$103.46M-0.51440
IRWD
Ironwood Pharmaceuticals
4.6826 of 5 stars
$0.75
+4.2%
$4.78
+540.3%
-87.3%$120.39M$351.41M-3.72220
ACHV
Achieve Life Sciences
1.6519 of 5 stars
$2.20
-2.9%
$14.33
+553.0%
-48.8%$76.49MN/A-1.6520
FBIO
Fortress Biotech
2.1611 of 5 stars
$1.85
-0.8%
$21.00
+1,038.2%
+15.7%$54.56M$57.67M-0.83170
CRIS
Curis
2.8896 of 5 stars
$2.30
-1.1%
$17.00
+640.7%
-73.3%$24.01M$10.91M-0.3760

Related Companies and Tools


This page (NASDAQ:DOMH) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners